Lowest Price Guaranteed
Pages
191
Last Updated
April 2026
View Count
16328
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Continuous Bioprocessing
3.3. Continuous Processing in the Pharmaceutical Industry
3.3.1. Regulatory Landscape
3.3.2. Early Adopters of the Technology
3.3.3. Anticipated Shift from Batch Processing
3.3.4. Advantages of Continuous Processing
3.3.5. Key Challenges Associated with Continuous Processing
3.3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Continuous and Semi-Continuous Bioprocessing: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Type of Manufacturer
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Company Size and Type of Manufacturer
4.2.6. Analysis by Location of Headquarters
4.2.7. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Innovators
4.2.8. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Contract Service Providers
4.2.9. Analysis by Type of Facility
4.2.10. Analysis by Type of Bioreactor
4.2.11. Analysis by Stage of Bioprocess
4.2.11.1. Primary Continuous and Semi-Continuous Bioprocessing
4.2.11.2. Secondary Continuous and Semi-Continuous Bioprocessing
4.2.12. Analysis by Types of Biologics Manufactured
4.2.13. Information on Production Capacity
5. CONTINUOUS BIOPROCESSING IN NORTH AMERICA: COMPANY PROFILES
5.1. Chapter Overview
5.2. AGC Biologics
5.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.2.2. Recent Developments and Future Outlook
5.3. Biogen
5.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.3.2. Recent Developments and Future Outlook
5.4. Bristol-Myers Squibb
5.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.4.2. Recent Developments and Future Outlook
5.5. Sanofi Genzyme
5.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.5.2. Recent Developments and Future Outlook
6. CONTINUOUS BIOPROCESSING IN EUROPE: COMPANY PROFILES
6.1. Chapter Overview
6.2. FUJIFILM Diosynth Biotechnologies
6.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.2.2. Recent Developments and Future Outlook
6.3. Merck KGaA
6.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.3.2. Recent Developments and Future Outlook
6.4. Novasep
6.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.4.2. Recent Developments and Future Outlook
6.5. UCB Pharma
6.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.5.2. Recent Developments and Future Outlook
7. CONTINUOUS BIOPROCESSING IN ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Enzene Biosciences
7.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
7.2.2. Recent Developments and Future Outlook
7.3. WuXi Biologics
7.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
7.3.2. Recent Developments and Future Outlook
8. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS BIOPROCESSING CAPABILITIES
8.1. Chapter Overview
8.2. Continuous Manufacturing Initiatives of Leading Companies
8.2.1. AbbVie
8.2.1.1. Partnered Initiatives
8.2.1.2. In-House Initiatives
8.2.2. Amgen
8.2.2.1. Partnered Initiatives
8.2.2.2. In-House Initiatives
8.2.3. Bristol-Myers Squibb
8.2.3.1. Partnered Initiatives
8.2.3.2. In-House Initiatives
8.2.4. GlaxoSmithKline
8.2.4.1. Partnered Initiatives
8.2.4.2. In-House Initiatives
8.2.5. Merck
8.2.5.1. Partnered Initiatives
8.2.5.2. In-House Initiatives
8.2.6. Novartis
8.2.6.1. Partnered Initiatives
8.2.6.2. In-House Initiatives
8.2.7. Pfizer
8.2.7.1. Initiatives
8.2.7.2. In-House Initiatives
8.2.8. Roche
8.2.8.1. Partnered Initiatives
8.2.8.2. In-House Initiatives
8.2.9. Sanofi
8.2.9.1. Partnered Initiatives
8.2.9.2. In-House Initiatives
9. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGICS: MARKET LANDSCAPE
9.1. Chapter Overview
9.2. Continuous Manufacturing Equipment for Biologic Drugs: Overall Market Landscape
9.2.1. Analysis by Type of Equipment
9.2.2. Analysis by Type of Manufacturing Process
9.2.3. Analysis by Stage of Bioprocess
9.2.4. Analysis by Scale of Operation
9.3. Continuous Manufacturing Equipment Providers for Biologics
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Analysis by Prominent Continuous Manufacturing Equipment Providers
10. COST SAVING ANALYSIS
10.1. Chapter Overview
10.2. Technologies Involved in Continuous and Semi-Continuous Bioprocessing
10.3. Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing
10.3.1. Potential Cost Savings in Upstream Processes
10.3.2. Potential Cost Savings in Downstream Processes
10.4. Key Assumptions and Methodology
10.5. Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocesses, Till 2035
10.6. Concluding Remarks
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.2.1. Global, Continuous and Semi-Continuous Bioprocessing Capacity
11.2.2. Analysis by Company Size
11.2.3. Analysis by Type of Manufacturer
11.2.4. Analysis by Company Size and Type of Manufacturer
11.2.5. Analysis by Scale of Operation
11.2.6. Analysis by Location of Headquarters
11.2.7. Analysis by Location of Continuous and Semi-Continuous Bioprocessing Facilities
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Continuous and Semi-Continuous Bioprocessing Market, Till 2035
12.3.1. Continuous and Semi-Continuous Bioprocessing Market, Till 2035: Distribution by Type of Manufacturer
12.3.2. Continuous and Semi-Continuous Bioprocessing Market, Till 2035: Distribution by Company Size
12.3.3. Continuous and Semi-Continuous Bioprocessing Market, Till 2035: Distribution by Scale of Operation
12.3.4. Continuous and Semi-Continuous Bioprocessing Market, Till 2035: Distribution by Stage of Bioprocess
12.3.5. Continuous and Semi-Continuous Bioprocessing Market, Till 2035: Distribution by Key Geographical Regions
12.4. Continuous Upstream Bioprocessing Market, Till 2035
12.4.1. Continuous Upstream Bioprocessing Market, Till 2035: Distribution by Type of Manufacturer
12.4.2. Continuous Upstream Bioprocessing Market, Till 2035: Distribution by Company Size
12.4.3. Continuous Upstream Bioprocessing Market, Till 2035: Distribution by Scale of Operation
12.4.4. Continuous Upstream Bioprocessing Market, Till 2035: Distribution by Key Geographical Regions
12.5. Continuous Downstream Bioprocessing Market, Till 2035
12.5.1. Continuous Downstream Bioprocessing Market, Till 2035: Distribution by Type of Manufacturer
12.5.2. Continuous Downstream Bioprocessing Market, Till 2035: Distribution by Company Size
12.5.3. Continuous Downstream Bioprocessing Market, Till 2035: Distribution by Scale of Operation
12.5.4. Continuous Downstream Bioprocessing Market, Till 2035: Distribution by Key Geographical Regions
13. CONCLUSION
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. AstraZeneca
14.2.1. Overview of Company / Organization
14.2.2. Interview Transcript: Jon Coffman, Senior Director of Bioprocess Technology and Engineering
14.3. Enzene Biosciences
14.3.1. Overview of Company / Organization
14.3.2. Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer
14.4. Albany College of Pharmacy and Health Sciences
14.4.1. Overview of Company / Organization
14.4.2. Interview Transcript: Ehsan Mahdinia, Assistant Professor
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Advantages of Continuous Bioprocessing
Figure 4.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
Figure 4.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
Figure 4.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
Figure 4.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
Figure 4.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
Figure 4.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
Figure 4.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Facilities of Innovators
Figure 4.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
Figure 4.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
Figure 4.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
Figure 4.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
Figure 4.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
Figure 4.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
Figure 4.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
Figure 4.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
Figure 8.1 Continuous Manufacturing Initiatives: AbbVie
Figure 8.2 Continuous Manufacturing Initiatives: Amgen
Figure 8.3 Continuous Manufacturing Initiatives: Bristol-Myers Squibb
Figure 8.4 Continuous Manufacturing Initiatives: GlaxoSmithKline
Figure 8.5 Continuous Manufacturing Initiatives: Merck
Figure 8.6 Continuous Manufacturing Initiatives: Novartis
Figure 8.7 Continuous Manufacturing Initiatives: Pfizer
Figure 8.8 Continuous Manufacturing Initiatives: Roche
Figure 8.9 Continuous Manufacturing Initiatives: Sanofi
Figure 9.1 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Figure 9.2 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Figure 9.3 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
Figure 9.4 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Figure 9.5 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Figure 9.6 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Figure 9.7 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Figure 9.8 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
Figure 10.1 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
Figure 10.2 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocess Techniques, 2021-2030 (USD Billion)
Figure 11.1 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
Figure 11.2 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
Figure 11.3 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
Figure 11.4 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
Figure 11.5 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
Figure 11.6 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
Figure 11.7 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
Figure 12.1 Overall Continuous and Semi-Continuous Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.2 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.3 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.4 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.5 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
Figure 12.6 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 12.7 Continuous Upstream Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.8 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.9 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.10 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.11 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 12.12 Continuous Downstream Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.13 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.14 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.15 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.16 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 13.1 Concluding Remarks: Market Landscape
Figure 13.2 Concluding Remarks: Capacity Analysis
Figure 13.3 Concluding Remarks: Recent Expansions
Figure 13.4 Concluding Remarks: Cost Saving Analysis
Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis for Continuous and Semi-Continuous Bioprocessing Market
Table 3.1 Early Adopters of Continuous Bioprocess Technology
Table 3.2 Batch Processing Technique versus Continuous Processing Technique: Comparison of Characteristics
Table 4.1 List of Companies with Expertise in Continuous and Semi-Continuous Bioprocessing
Table 4.2 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Scale of Operation
Table 4.3 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Type of Facility and Type of Bioreactor
Table 4.4 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Stage of Bioprocess
Table 4.5 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Primary Continuous and Semi-Continuous Bioprocessing
Table 4.6 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Secondary Continuous and Semi-Continuous Bioprocessing
Table 4.7 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Types of Biologics Manufactured
Table 4.8 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Production Capacity
Table 5.1 AGC Biologics: Company Snapshot
Table 5.2 AGC Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.3 AGC Biologics: Recent Developments and Future Outlook
Table 5.4 Biogen: Company Snapshot
Table 5.5 Biogen: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.6 Biogen: Recent Developments and Future Outlook
Table 5.7 Bristol-Myers Squibb: Company Snapshot
Table 5.8 Bristol-Myers Squibb: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.9 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 5.10 Sanofi Genzyme: Company Snapshot
Table 5.11 Sanofi Genzyme: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.12 Sanofi Genzyme: Recent Developments and Future Outlook
Table 6.1 FUJIFILM Diosynth Biotechnologies: Company Snapshot
Table 6.2 FUJIFILM Diosynth Biotechnologies: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.3 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.4 Merck KGaA: Company Snapshot
Table 6.5 Merck KGaA: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.6 Merck KGaA: Recent Developments and Future Outlook
Table 6.7 Novasep: Company Snapshot
Table 6.8 Novasep: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.9 Novasep: Recent Developments and Future Outlook
Table 6.10 UCB Pharma: Company Snapshot
Table 6.11 UCB Pharma: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.12 UCB Pharma: Recent Developments and Future Outlook
Table 7.1 Enzene Biosciences: Company Snapshot
Table 7.2 Enzene Biosciences: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 7.3 Enzene Biosciences: Recent Developments and Future Outlook
Table 7.4 WuXi Biologics: Company Snapshot
Table 7.5 WuXi Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 7.6 WuXi Biologics: Recent Developments and Future Outlook
Table 8.1 AbbVie: Partnered Initiatives
Table 8.2 AbbVie: In-House Initiatives
Table 8.3 Amgen: Partnered Initiatives
Table 8.4 Amgen: In-House Initiatives
Table 8.5 Bristol-Myers Squibb: Partnered Initiatives
Table 8.6 Bristol-Myers Squibb: In-House Initiatives
Table 8.7 GlaxoSmithKline: Partnered Initiatives
Table 8.8 GlaxoSmithKline: In-House Initiatives
Table 8.9 Merck: Partnered Initiatives
Table 8.10 Merck: In-House Initiatives
Table 8.11 Novartis: Partnered Initiatives
Table 8.12 Novartis: In-House Initiatives
Table 8.13 Pfizer: Partnered Initiatives
Table 8.14 Pfizer: In-House Initiatives
Table 8.15 Roche: Partnered Initiatives
Table 8.16 Roche: In-House Initiatives
Table 8.17 Sanofi: Partnered Initiatives
Table 8.18 Sanofi: In-House Initiatives
Table 9.1 Continuous Manufacturing Equipment for Biologics: Information on Type of Equipment, Type of Manufacturing Process and Stage of Bioprocess
Table 9.2 Continuous Manufacturing Equipment for Biologics: Information on Scale of Operation and Throughput / Capacity
Table 9.3 Continuous Manufacturing Equipment Providers for Biologics: Information of Year of Establishment, Company Size and Location of Headquarters
Table 10.1 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Upstream Process
Table 10.2 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential of AcuSyst Perfusion Bioreactors
Table 10.3 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Downstream Process
Table 11.1 Global Continuous and Semi-Continuous Bioprocessing Capacity: Average Upstream Capacity by Company Size (Sample Data Set)
Table 14.1 AstraZeneca: Company / Organization Snapshot
Table 14.2 Enzene Biosciences: Company / Organization Snapshot
Table 14.3 Albany College of Pharmacy and Health Sciences: Company / Organization Snapshot
Table 15.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
Table 15.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
Table 15.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
Table 15.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
Table 15.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
Table 15.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
Table 15.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Innovators
Table 15.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
Table 15.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
Table 15.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
Table 15.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
Table 15.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
Table 15.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
Table 15.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
Table 15.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
Table 15.16 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Table 15.17 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Table 15.18 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
Table 15.19 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Table 15.20 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Table 15.21 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Table 15.22 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Table 15.23 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
Table 15.24 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
Table 15.25 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing Techniques, 2021-2030 (USD Billion)
Table 15.26 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
Table 15.27 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
Table 15.28 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
Table 15.29 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
Table 15.30 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
Table 15.31 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
Table 15.32 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
Table 15.33 Overall Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030
Table 15.34 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.35 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.36 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.37 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
Table 15.38 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Table 15.39 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.40 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.41 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.42 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.43 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Table 15.44 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.45 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.46 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.47 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.48 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Please reach out to our team for more details.